Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from Approvals

More from Product Reviews